GlassScriptPhysician profile
Brittany Huffman
NPI 1043938822
$4,163.37
in general payments reported to CMS, 2019-2025
22 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $1,315 · 2024: $1,017 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.74 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $561.77 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.41 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $407.05 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $389.44 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $384.47 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $337.94 | 2023-2025 | Aristada, Lybalvi |
| Abbvie INC. | $293.56 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $256.39 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $244.59 | 2023-2025 | Rexulti |
| Corium, LLC | $217.86 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $173.91 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $114.65 | 2023-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $106.51 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $86.74 | 2022-2025 | Spravato |
| Luye Pharma (USA) LTD. | $29.42 | 2025 | Erzofri Extended-Release |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.79 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.85 | 2025 | Rejoyn |
| Bausch Health US, LLC | $19.73 | 2022 | |
| Harmony Biosciences LLC | $18.44 | 2023 | Wakix |
| Acadia Pharmaceuticals INC | $18.29 | 2023 | Nuplazid |
| Tris Pharma INC | $17.92 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $15.64 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.